• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    LifeLens Technologies Expands Executive Leadership Team and Board of Directors

    11/8/23 7:30:00 AM ET
    $INSP
    $TCMD
    Medical/Dental Instruments
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $INSP alert in real time by email

    PHILADELPHIA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- LifeLens Technologies, Inc. (LifeLens), a medical technology company that provides real-time physiological monitoring, today announced the appointment of three industry veterans to the following positions on its executive leadership team and Board of Directors:

    • Daniel J. Sullivan, Chairman of the Board of LifeLens, as Chief Executive Officer
    • Brent A. Moen as Chief Financial Officer
    • Richard J. Buchholz as a member of the Board of Directors

    "With LifeLens, we have a significant opportunity to disrupt healthcare and make a meaningful impact on patients and healthcare professionals, and we are thrilled to have Brent and Rick join the LifeLens team," said Dan Sullivan, Chief Executive Officer and Chairman of the Board of Directors of LifeLens. "Brent and Rick collectively bring over 60 years of combined experience and track records that have led to business growth while transforming clinical care, and now their skills will help enable LifeLens to realize its potential."  

    Daniel Sullivan has served as Chairman of the Board of Directors of LifeLens and assumed the additional role of Chief Executive Officer of LifeLens effective January 2023. Mr. Sullivan brings over 40 years of leadership in the medical device industry where he has been a principal, chief executive officer, board member or co-founder of 11 separate start-up companies, 10 of which have been acquired. These companies include SciMed Life Systems, Inc., which was acquired by Boston Scientific Corporation in 1995, The WATCHMAN (Atritech, Inc.), which was acquired by Boston Scientific Corporation in 2011, superDimension, Ltd., which was acquired by Covidien plc in 2012 and NeuWave Medical, Inc., which was acquired by Johnson & Johnson in 2016.

    Brent Moen was appointed to the position of Chief Financial Officer effective September 2023 and has over 30 years of experience in finance. Mr. Moen most recently served as the Chief Financial Officer of Tactile Systems Technology, Inc. (NASDAQ:TCMD), a publicly traded medical device company, from September 2018 until March 2023. Prior to joining Tactile Systems Technology, Mr. Moen served as Chief Financial Officer of Entellus Medical, Inc., a publicly traded medical device company, from 2016 until its acquisition by Stryker Corporation in 2018. Mr. Moen also served as the Chief Financial Officer of ABRA Auto Body & Glass LP, as well as the Chief Financial Officer of Regis Corporation.

    Richard Buchholz was appointed to the LifeLens' Board of Directors, effective October 2023. Since 2014, Mr. Buchholz has served as the Chief Financial Officer of Inspire Medical Systems, Inc. (NYSE:INSP), a global leader in the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Prior to joining Inspire, Mr. Buchholz served as the Chief Financial Officer at superDimension, Ltd. from 2006 to 2013. Mr. Buchholz also served as the Chief Financial Officer of Vascular Solutions, Inc., which was acquired by Teleflex Incorporated in 2017.

    About LifeLens Technologies, Inc.

    LifeLens, a private healthcare company, has developed a revolutionary system incorporating artificial intelligence capable of monitoring physiological data to assess real-time health readiness and performance. The LifeLens system can provide monitoring both remotely and, in the hospital, or doctors' office and can wirelessly transmit real‐time scenarios providing actionable information that will allow health professionals to make data-driven decisions to improve the health and welfare of patients. The LifeLens product is FDA-cleared for the indication of remote single channel electrocardiogram (ECG) and heart rate monitoring. The system is not yet FDA cleared for other indications.

    Since 2019, LifeLens has been testing its wearable physiological sensors with the United States Armed Forces, allowing military leaders the ability to monitor their troops health, readiness, and performance in real-time training and operational environments. For more information, please visit www.lifelenstech.com.

    Inquiries:

    Dan Sullivan, CEO

    [email protected]

    Brent Moen, CFO

    [email protected]



    Primary Logo

    Get the next $INSP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INSP
    $TCMD

    CompanyDatePrice TargetRatingAnalyst
    Inspire Medical Systems Inc.
    $INSP
    2/13/2026Outperform → Peer Perform
    Wolfe Research
    Inspire Medical Systems Inc.
    $INSP
    2/12/2026$74.00Outperform → Neutral
    Robert W. Baird
    Inspire Medical Systems Inc.
    $INSP
    2/12/2026$70.00Overweight → Equal Weight
    Wells Fargo
    Inspire Medical Systems Inc.
    $INSP
    1/27/2026$90.00Outperform → Sector Perform
    RBC Capital Mkts
    Inspire Medical Systems Inc.
    $INSP
    1/22/2026$96.00Buy → Hold
    Truist
    Inspire Medical Systems Inc.
    $INSP
    1/22/2026Outperform → Perform
    Oppenheimer
    Tactile Systems Technology Inc.
    $TCMD
    1/5/2026$35.00Neutral → Overweight
    Piper Sandler
    Inspire Medical Systems Inc.
    $INSP
    12/8/2025$175.00Perform → Outperform
    Oppenheimer
    More analyst ratings

    $INSP
    $TCMD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 21, 2023 - FDA Roundup: March 21, 2023

    For Immediate Release: March 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA completed its second pre-market consultation for a human food made from cultured animal cells. The firm will use animal cell culture technology to take living cells from chickens and grow the cells in a controlled environment to make the cultured

    3/21/23 3:12:46 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    $INSP
    $TCMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Inspire Medical Systems downgraded by Wolfe Research

    Wolfe Research downgraded Inspire Medical Systems from Outperform to Peer Perform

    2/13/26 8:29:00 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Inspire Medical Systems downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded Inspire Medical Systems from Outperform to Neutral and set a new price target of $74.00

    2/12/26 7:22:54 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Inspire Medical Systems downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Inspire Medical Systems from Overweight to Equal Weight and set a new price target of $70.00

    2/12/26 7:22:44 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    $INSP
    $TCMD
    SEC Filings

    View All

    SEC Form 144 filed by Tactile Systems Technology Inc.

    144 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)

    2/24/26 4:29:52 PM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Inspire Medical Systems Inc.

    SCHEDULE 13G/A - Inspire Medical Systems, Inc. (0001609550) (Subject)

    2/17/26 4:49:04 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by Tactile Systems Technology Inc.

    10-K - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Filer)

    2/17/26 4:06:15 PM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    $INSP
    $TCMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tactile Systems Technology, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

    MINNEAPOLIS, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Summary: Total revenue increased 21% year-over-year to $103.6 millionGross margin of 78% versus 75% in Q4 2024Net income of $10.6 million versus $9.7 million in Q4 2024Adjusted EBITDA of $22.9 million versus $16.2 million in Q4 2024 Full Year 2025 Summary: Total revenue increased 12% year-over-year to $329.5 millionGross margin of 76%, compared to 74% in 2024Oper

    2/17/26 4:05:00 PM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    Tactile Medical Acquires LymphaTech, Expanding Breadth and Depth of its Lymphedema Solutions Portfolio

    MINNEAPOLIS, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that it has acquired LymphaTech Inc., for an upfront cash payment at closing of $6.8 million, plus potential additional consideration that is contingent upon the achievement of future milestones. Founded in 2014, LymphaTech, Inc. is a privately held medical technology company pioneering a digital, three-dimensional ("3D") full body measurement and monitoring platform designed specifically for lymphedema. Damage to the lymphatic system from chronic fluid accumulat

    2/17/26 4:04:00 PM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    Inspire Medical Systems, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results

    Fourth quarter revenue growth of 12% and full year revenue growth of 14%Fourth quarter net income per diluted share of $4.66; adjusted net income per diluted share of $1.65Full year net income per diluted share of $4.89; adjusted net income per diluted share of $2.42Operating cash flow of $52.5 million in the fourth quarter with full year operating cash flow of $117.0 million MINNEAPOLIS, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter and

    2/11/26 4:02:00 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    $INSP
    $TCMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Dodd Sheri Louise sold $318,144 worth of shares (10,993 units at $28.94), decreasing direct ownership by 4% to 243,885 units (SEC Form 4)

    4 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)

    2/26/26 4:57:21 PM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    CHIEF FINANCIAL OFFICER Birkemeyer Elaine M. sold $222,880 worth of shares (7,701 units at $28.94), decreasing direct ownership by 5% to 134,819 units (SEC Form 4)

    4 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)

    2/26/26 4:56:04 PM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    Sr. VP Mktg & Clinical Affairs Burns Kristie sold $180,764 worth of shares (6,246 units at $28.94), decreasing direct ownership by 7% to 82,581 units (SEC Form 4)

    4 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)

    2/26/26 4:55:36 PM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    $INSP
    $TCMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Curet Myriam bought $804 worth of shares (5 units at $160.72) and sold $616 worth of shares (6 units at $102.59), decreasing direct ownership by 0.03% to 3,365 units (SEC Form 4)

    4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)

    11/24/25 8:40:17 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Sparks Charisse Y bought $15,350 worth of shares (100 units at $153.50), increasing direct ownership by 11% to 998 units (SEC Form 4)

    4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)

    1/24/24 4:32:03 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    $INSP
    $TCMD
    Leadership Updates

    Live Leadership Updates

    View All

    Inspire Medical Systems, Inc. Announces Preliminary Unaudited Revenue Results for the Fourth Quarter and Full Year 2025 and Provides Initial 2026 Revenue Guidance

    MINNEAPOLIS, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) ("Inspire", or the "Company"), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today announced certain preliminary, unaudited results for the fourth quarter and full year ended December 31, 2025, and provided its initial full year 2026 revenue guidance. Further, the Company announced the appointment of Matt Osberg as Executive Vice President and Chief Financial Officer. Preliminary, Unaudited Fourth Quarter and Full Year 2025 Revenue Revenue for the fourth quarter of 2025 is anticipate

    1/12/26 6:45:00 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Inspire Medical Systems, Inc. Announces the Addition of Paul T. Hoff, M.D., M.S. and Ruchir P. Patel, M.D., F.A.C.P. as Vice President, Senior Medical Directors

    MINNEAPOLIS, April 21, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced that two leading physicians in the field of sleep medicine and sleep surgery, Paul T. Hoff, M.D., M.S., an otolaryngologist, and Ruchir P. Patel, M.D., F.A.C.P., a sleep medicine specialist, will join Inspire in Vice President, Senior Medical Director roles, effective April 21 and June 2 respectively.   "Dr. Hoff and Dr. Patel are widely regarded as experts and thought leaders in their respective fields, a

    4/21/25 8:00:00 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Tactile Medical Appoints Laura King to Board of Directors

    MINNEAPOLIS, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced the appointment of Laura King to the Company's Board of Directors ("Board") and as a member of the Audit and Compliance & Reimbursement Committees, effective January 13, 2025. Ms. King is a seasoned healthcare executive with a proven track record of leadership and developing innovative products that enhance patient care. Her extensive experience includes a 22-year career at General Electric Company (GE), where she served as a Company Officer in her role as President & CEO of GE

    1/13/25 8:00:00 AM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    $INSP
    $TCMD
    Financials

    Live finance-specific insights

    View All

    Tactile Systems Technology, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

    MINNEAPOLIS, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Summary: Total revenue increased 21% year-over-year to $103.6 millionGross margin of 78% versus 75% in Q4 2024Net income of $10.6 million versus $9.7 million in Q4 2024Adjusted EBITDA of $22.9 million versus $16.2 million in Q4 2024 Full Year 2025 Summary: Total revenue increased 12% year-over-year to $329.5 millionGross margin of 76%, compared to 74% in 2024Oper

    2/17/26 4:05:00 PM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    Tactile Medical Acquires LymphaTech, Expanding Breadth and Depth of its Lymphedema Solutions Portfolio

    MINNEAPOLIS, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that it has acquired LymphaTech Inc., for an upfront cash payment at closing of $6.8 million, plus potential additional consideration that is contingent upon the achievement of future milestones. Founded in 2014, LymphaTech, Inc. is a privately held medical technology company pioneering a digital, three-dimensional ("3D") full body measurement and monitoring platform designed specifically for lymphedema. Damage to the lymphatic system from chronic fluid accumulat

    2/17/26 4:04:00 PM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    Inspire Medical Systems, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results

    Fourth quarter revenue growth of 12% and full year revenue growth of 14%Fourth quarter net income per diluted share of $4.66; adjusted net income per diluted share of $1.65Full year net income per diluted share of $4.89; adjusted net income per diluted share of $2.42Operating cash flow of $52.5 million in the fourth quarter with full year operating cash flow of $117.0 million MINNEAPOLIS, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter and

    2/11/26 4:02:00 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    $INSP
    $TCMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Tactile Systems Technology Inc.

    SC 13G/A - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)

    11/13/24 7:29:11 PM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Tactile Systems Technology Inc.

    SC 13G - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)

    11/13/24 5:04:27 PM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Inspire Medical Systems Inc.

    SC 13G/A - Inspire Medical Systems, Inc. (0001609550) (Subject)

    11/12/24 10:32:14 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care